
    
      Main inclusion criteria:

        1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification

        2. Age â‰¥ 18 years

        3. Concurrent participation in clinical trials will be allowed.

      Efficacy assessments will be evaluated by: HMR mutations rate, specific HMR mutations,
      disease duration, presence of splenomegaly, cytogenetic risk, DIPPS, IPSS, ET survival score
      and PV survival score.

      The primary efficacy parameter to be assessed will be HMR mutation rate.
    
  